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Background: Our previous studies suggest silkworms can be used as model animals instead of mammals in
pharmacologic studies to develop novel therapeutic medicines. We examined the usefulness of the silkworm larvae
Bombyx mori as an animal model for evaluating tissue injury induced by various cytotoxic drugs. Drugs that induce
hepatotoxic effects in mammals were injected into the silkworm hemocoel, and alanine aminotransferase (ALT)
activity was measured in the hemolymph 1 day later.
Results: Injection of CCl4 into the hemocoel led to an increase in ALT activity. The increase in ALT activity was
attenuated by pretreatment with N-acetyl-L-cysteine. Injection of benzoic acid derivatives, ferric sulfate, sodium valproate,
tetracycline, amiodarone hydrochloride, methyldopa, ketoconazole, pemoline (Betanamin), N-nitroso-fenfluramine, and
D-galactosamine also increased ALT activity.
Conclusions: These findings indicate that silkworms are useful for evaluating the effects of chemicals that induce tissue
injury in mammals.
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Tissue injury induced by chemicals in mammals, includ-
ing humans, is associated with the rapid development of
severe impairment of the organs involved in detoxifica-
tion, e.g., fulminant hepatic failure [1]. Therefore, assess-
ment of chemical-induced tissue injury is crucial in drug
discovery.
In the development of novel therapeutic medicines,
in vivo trials using animal models are essential for pre-
dicting toxicity and drug disposition in the human body.
Mice and rats are used to evaluate the toxicity of synthe-
sized compounds and natural medicines [2-4]. The use
of mammals for experimental models, however, is asso-
ciated with a number of problems, such as high cost and
ethical issues. An alternative animal model is needed to
overcome these problems.* Correspondence: sekimizu@mol.f.u-tokyo.ac.jp
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reproduction in any medium, provided the orAlthough invertebrate animals such as Caenorhabditis
elegans (C. elegans) and Drosophila larvae have been
proposed as model animals for evaluating bacterial
pathogenicity and therapeutic effects of antibiotics, their
body sizes are too small to inject a fixed amount of sam-
ple [5,6]. Large insect larvae can be easily injected into
the midgut or subcutaneously with sample solution
using a syringe. Silkworm hemolymph and tissue can be
harvested separately and used in biochemical, haemato-
logical, and immunological analyses [7,8]. Thus, the silk-
worm is an invertebrate model that can relieve the
issues related to the use of mammals and thus promote
pharmaceutical studies [7,9-12]. We previously demon-
strated that the lethal dose of various cytotoxic sub-
stances in silkworms is consistent with that in mammals
[7]. Thus, silkworms are considered to be appropriate
for evaluating the toxic effects of chemical compounds
on animal bodies. In mammals, hepatotoxic substances
induce increases in marker enzymes of tissue injury in
the blood [13]. Increases in alanine aminotransferase
(ALT) activity in mammalian blood are caused by leak-
age of this enzyme from injured tissue. ALT is conservedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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be a surrogate marker of tissue injury in insect larvae.
To date, however, there has been no evidence that ALT
activity is increased in the body fluid of the silkworm
upon the induction of tissue injury.
The present study aimed to examine ALT activity in
the body fluid of silkworm larvae injected with various
hepatotoxic compounds. We also analyzed the effect-
iveness of using the silkworm model for evaluating




Various cytotoxic drugs were purchased, as follows: carbon
tetrachloride (CCl4), salicylic acid, ferric sulfate, sodium
valproate, N-nitroso-fenfluramine, and D-galactosamine
were purchased from Wako Pure Chemical Industries,
Osaka, Japan; acetaminophen was purchased from Tocris
Biosciences, Ellisville, MO; acetylsalicylic acid was pur-
chased from Cayman Chemical Co., Ann Arbor, MI; tetra-
cycline was purchased from LKT Laboratories Inc., St
Paul, MN; amiodarone hydrochloride was purchased from
MP Biomedicals, Solon, OH; methyldopa was purchased
from Sawai Pharmaceutical Co., Ltd., Osaka, Japan; ketoco-
nazole was purchased from LKT Laboratories Inc.; and
pemoline was purchased from Sanwa Kagaku Kenkyusho
Co., Ltd., Nagoya, Japan. N-acetyl-L-cysteine (NAC), which
acts to suppress increases in ALT activity, was purchased
from Sigma-Aldrich, St. Louis, MO. Hydrosoluble and
liposoluble compounds were dissolved in saline and di-
methyl sulfoxide, respectively.
Animals
Fertilized silkworm eggs (Bombyx mori, Hu·Yo × Tuku-
ba·Ne) were purchased from Ehime Sanshu Co., Ltd.
(Ehime, Japan). Hatched larvae were fed artificial food,
Silkmate 2S (Nosan Corporation, Yokohama, Japan) at
27°C.
Construction of cytotoxic induction model using silkworm
larvae
Fifth-instar silkworm larvae on the first day were fed
artificial food, Silkmate 2S, for 1 d. After the body
weight increased to 1.8 to 2.2 g, they were fasted for 6 h,
and solution containing a cytotoxic compound was
injected into the hemocoel from the backside of the lar-
vae. Liposoluble compounds were injected (25 μL/silk-
worm) using a glass syringe (MICROLITER™ #710,
Hamilton Co., Reno, NV) with a 27G needle, and hydro-
soluble compounds were injected (50 μL/silkworm)
using a disposable syringe (Terumo Corporation, Tokyo,
Japan) with a 27G needle. After incubation at 27°C for1 d, the hemolymph was collected for measurement of
ALT activity as described below.
Examination of suppressive effects against induced
cytotoxicity
Fifth-instar silkworm larvae on the first day were fed
Silkmate 2S for 1 d. After the body weight increased to
1.8 to 2.2 g, they were fasted for 6 h, and 50 μL of 0.9%
saline or 0.4 M NAC was injected into hemocoel from
the backside of the larvae using a disposable syringe.
After 30 min, 25 μL of olive oil or 15% CCl4 was injected
into the hemocoel using a glass syringe. After incubation
at 27°C for 1 d, the hemolymph was collected for meas-
urement of ALT activity as described below.
Preparation of tissue homogenates from silkworm larvae
Fifth-instar silkworm larvae on the first day were fed Silk-
mate 2S for 1 d. After fasting for 6 h, the gut, fat body, silk
gland, Malpighian tube, and outer coat were isolated. Each
tissue was weighed and homogenized with insect physio-
logic saline (150 mM NaCl, 5 mM KCl, 1 mM CaCl2).
Samples were centrifuged at 3000 rpm for 5 min, and the
supernatant was collected and stored at −80°C until meas-
urement of ALT activity. The amount of protein in the
supernatant was quantified using Lowry’s method.
Measurement of ALT activity
Five μL of collected hemolymph or the supernatant of
homogenized tissue was mixed with 550 μL of a reaction
solution containing 0.5 M L-alanine, 0.2 mM NADH, 1.3
U/mL lactate dehydrogenase, and 0.9 mg/mL bovine
serum albumin. After adding 50 μL of 180 mM 2-
oxoglutarate solution, the reaction mixtures were incu-
bated at 30°C for 90 min. Absorbance at 339 nm was
recorded to detect decreases in NADH. The slope of the
absorbance decrease is proportional to ALT activity.
Final ALT activities were determined according to the
standard curve drawn from the results of mouse liver
homogenate. For ALT activity, 1U was defined as the en-
zyme activity that forms 1 μmol NAD/min under the
assay conditions.
Statistical analysis
All experiments were performed at least twice and the
data are shown as the mean ± standard deviation. The
significance of differences was calculated using a 2-tailed
Student's t-test at the significance level alpha = 0.05.
Results
Elevation of ALT activity in the hemolymph of silkworms
injected with carbon tetrachloride (CCl4)
CCl4 is generally used as a model compound to evaluate
hepatotoxic effects in mammals. Tissue injury induced
by CCl4 is considered to increase ALT activity in the
Table 1 Tissue distribution of ALT activity in silkworm
Tissue Total activity Protein Specific activity
(U/tissue) (mg) (U/mg)
Gut 7.0 4.7 1.5
Fat body 0.2 0.3 0.6
Silk grand 0.4 0.9 0.5
Malpighi grand 0.5 0.2 0.8
Outer coat 3.9 4.9 0.8
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ALT activity in silkworm hemolymph after injection of
CCl4. ALT activity in the silkworm hemolymph increased
8-fold following injection of CCl4 compared with injec-
tion of olive oil (Figure 1). This finding suggests that tis-
sue injury can be monitored in silkworms by measuring
ALT activity. In the subsequent experiments, we used
CCl4 as a positive control and 0.9% saline or olive oil as
a negative control.
Tissue distribution of ALT activity in silkworms
ALT localizes in the liver and muscles in mammals.
Localization of ALT activity in the silkworm has not yet
been reported. We determined the tissue distribution of
ALT activity to determine which tissue produces ALT ac-
tivity in the silkworm hemolymph. The total activity and
specific activity of ALT in each tissue are shown in
Table 1. The highest total activity and the highest spe-
cific activity were detected in the gut.
Suppressive effects on ALT activity increases by
pretreatment with N-acetyl-L-cysteine (NAC)
As described above, CCl4 that is hepatotoxic in mam-
mals increased ALT activity in the silkworm hemolymph.
Therefore, we considered the silkworm applicable as an
animal model to evaluate drug-induced tissue injury. In
mammals, radical scavengers such as NAC suppress the
cytotoxic effects induced by hepatotoxic substances [15].
Pretreatment with NAC is useful for clarifying whether























Figure 1 ALT activity in the silkworm hemolymph injected with
CCl4. Silkworms fasted for 6 h were injected with 15% CCl4 or olive
oil, and then ALT activity in the silkworm hemolymph was measured
1 d later. (n = 5).due to the production of radicals. In this study, we
examined the effect of injecting the silkworm with NAC
prior to injection of CCl4 on ALT activity in the
hemolymph. The ALT activity of CCl4-injected silk-
worms that were preinjected with 0.4 M NAC was much
lower than those of silkworms preinjected with 0.9%
NaCl (Figure 2).
Increased ALT activity in the silkworm hemolymph
following injection with cytotoxic drugs
Consistent with the results described above, CCl4 was
suggested to induce tissue injury via the production of
radicals in the silkworm body. We then examined the in-
fluence of benzoic acid derivatives (acetaminophen, sali-
cylic acid, and acetylsalicylic acid), which are known
hepatotoxic agents due to the production of radicals by
the catalytic reaction of P450 2E1 [16-18], on ALT activ-
ity in the silkworm hemolymph. ALT activity in the
hemolymph increased in a dose-dependent manner
following injection of each of these agents (Figure 3).
Compared with the negative control, ALT activity was
increased in groups treated with 6 mg acetaminophen
(7-fold), 1.2 and 12 mg salicylic acid (9 and 10-fold, re-
spectively), and 1.8 and 18 mg acetylsalicylic acid (3 and
11-fold, respectively). Based on the amount of each drug
needed to increase ALT activity, salicylic acid was the
most toxic among these three reagents.
Substances that produce toxic effects by the production
of radicals were suggested to induce tissue injury in the
silkworm body and to subsequently increase ALT activity
in the silkworm hemolymph. It remains unclear, however,
whether tissue injury induced by various biological
mechanisms in mammals can be evaluated based on
increased ALT activity in the silkworm. Other substances
that induce tissue injury in mammals by different mechan-
isms were also examined to evaluate whether they would
induce increases in ALT activity in the silkworm
hemolymph. Excessive amounts of iron induce tissue in-
jury by radical production [19]. Sodium valproate, tetra-
cycline, and amiodarone induce tissue damage, probably
via inhibiting the function of cell organelles such as mito-
chondria and lysosomes [20-22]. Compared with the nega-
tive control, ALT activity clearly increased in groups
treated with 0.084 and 0.84 mg ferric acid (4 and 13-fold,
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Figure 2 ALT activity in the silkworm hemolymph injected with 0.4 M NAC prior to CCl4. Silkworms fasted for 6 h were injected with 0.4 M
NAC or 0.9% NaCl (first injection), and then injected with 15% CCl4, 20% CCl4 or 0.9% NaCl (the second injection) 30 min later. The hemolymph
was collected to measure ALT activity after 1 d incubation. The horizontal bar in each line indicates mean ALT activity in each group. *P < 0.01
and **P < 0.001 vs. 0.9% NaCl-0.9% NaCl, ***P < 0.01 vs. 0.9% NaCl-15% CCl4, and ****P < 0.001 vs. 0.9% NaCl-20% CCl4. (n = 5, 0.9% NaCl-0.9%
NaCl; n = 7, other groups).
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mg tetracycline (2 and 12-fold, respectively), and 0.16 and
1.6 mg amiodarone hydrochloride (2 and 13-fold, respect-
ively; Figure 4A).
We then examined the induction of tissue injury by
methyldopa, ketoconazole, and pemoline (Betanamin) in
the silkworm. These agents are thought to induce hep-
atic injury in mammals by the formation of metabolites
that cause immune hypersensitivity, such as eosinophilia
[23-25]. All of the reagents increased ALT activity (3.9
mg methyldopa, 6-fold; 1.6 mg ketoconazole, 2-fold; and
5.6 mg pemoline, 2-fold; Figure 4B).
Excessive intake of N-nitroso-fenfluramine, which is
generally used as a food supplement, has hepatotoxic
effects [26,27]. Rapid depletion of ATP by impaired

























Figure 3 ALT activity in the silkworm hemolymph injected with benz
acetaminophen, salicylic acid, or acetylsalicylic acid, and 1 d later the silkwo
***P < 0.001 vs. negative control. (n = 5).by the production of alkyl cations are thought to be the
mechanism of N-nitroso-fenfluramine-induced cell death
[28]. We tested whether silkworms can be used to detect
N-nitroso-fenfluramine-induced tissue injury by measur-
ing ALT activity in the hemolymph. ALT activity in the
hemolymph of silkworms injected with 450 μg
N-nitroso-fenfluramine increased 3-fold (Figure 5A).
D-Galactosamine is a hepatotoxin that induces the de-
pletion of uridine with subsequent necrosis [29]. This
compound is frequently used for the construction of
fulminant hepatic injury models [29]. Inhibition of the
synthesis of nucleic acids, proteins, and lipids by UDP-
glucosamine, which is derived from D-galactosamine, is
the suggested mechanism of tissue damage [29]. We
examined whether tissue injury was induced in silk-
worms by injection of D-galactosamine. ALT activity in.12 1.2 12 
alicylic acid (mg) 
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Figure 4 ALT activity in the silkworm hemolymph injected with various hepatotoxic drugs. Silkworms fasted 6 h were injected with ferric
sulfate, sodium valproate, tetracycline, or amiodarone hydrochloride (A), and with methyldopa, ketoconazole, or pemoline (B), and 1 d later the
silkworm hemolymph was collected to measure ALT activity. *P < 0.05, **P < 0.01 and ***P < 0.001 vs. negative control. (n = 5).
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increased compared with the negative control (injected
0.9% saline, 6-fold difference; Figure 5B).
Discussion
The findings of the present study demonstrate the applic-
ability of silkworm larvae as an animal model for evaluat-





























Figure 5 ALT activity in the silkworm hemolymph injected with N-nit
injected with N-nitroso-fenfluramine (A), and with injected D-galactosamine
ALT activity. **P < 0.01 and ***P < 0.001 vs. negative control. (n = 5).ALT activity in the hemolymph. ALT activity levels in
human blood are considered to be a highly sensitive and
fairly specific preclinical and clinical biomarker of cytotox-
icity or hepatotoxicity [13]; therefore, ALT activity levels
in the blood of mammals are measured in many pharma-
ceutical studies to evaluate the hepatotoxic effects induced
by natural products or newly synthesized chemicals. Here,




























roso-fenfluramine and D-galactosamine. Silkworms fasted 6 h were
(B), and 1 d later the silkworm hemolymph was collected to measure
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drugs into the hemocoel. The results strongly suggest that
we could establish a new experimental model to evaluate
tissue injury effects using silkworm larvae.
The silkworm has been progressively developed as a
scientifically useful experimental animal model [30].
Established silkworm models of infection with patho-
genic bacteria and true fungi have been used to evaluate
the effects of antibiotics and identify novel virulence
genes [31-35]. The established hyperglycemic silkworm
model is effective for developing antidiabetic drugs [36].
These studies suggest that silkworms can be used as
model animals instead of mammals, such as mice and
rats, in pharmacologic studies to develop novel thera-
peutic medicines. Furthermore, silkworms and mammals
have common metabolic pathways involving cytochrome
P450s and conjugation enzymes [7]. Cytotoxic effects on
tissue and subsequent processes such as the release of
marker enzymes from damaged cells occur similarly in
silkworms and mammals. In the present study, we showed
that ALT activity levels in the silkworm hemolymph were
increased by the administration of CCl4. In addition, the
increase in ALT activity induced by CCl4 administration
was suppressed by pretreatment with NAC, suggesting
that NAC suppressed CCl4-induced tissue injury. NAC is
a radical scavenger that attenuates hepatotoxic effects
induced in the mammalian liver and is used to treat
patients with acute acetaminophen hepatotoxicity [15,37].
The present result revealed that NAC has similar suppres-
sive effects in the silkworm body. This silkworm model is
thus considered to be useful not only for analyzing the
histotoxicity of compounds, but also for the discovery of
drugs that have protective effects against histotoxicity. Al-
though we demonstrated the tissue distribution of ALT ac-
tivity in the silkworm, the mechanism of tissue injury
induction detected by elevated ALT levels remains un-
clear. The present silkworm model can be used to rapidly
evaluate histotoxicity, but is not sufficient to elucidate the
specific target of drugs. Further studies are needed to clar-
ify the mechanism of tissue injury induction in silkworm.
The prediction of drug hepatotoxicity is crucial for
drug discovery and development. Although small mam-
mals such as mice and rats are generally used to evaluate
hepatotoxicity, their use is associated with several pro-
blems, such as high experimental costs and ethical
issues. In vitro assay systems using human hepatocytes
have been developed in an attempt to solve these pro-
blems [38-40]. Toxicogenomic systems are suggested to
be effective for predicting hepatotoxicity according to
the varied expression of hepatotoxicity-responsive genes
[41-43]. The collection of mammalian cells as a material
and the conditional differences from in vivo examin-
ation, however, remain problems in these in vitro assay
systems. The silkworm tissue injury model established inthe present study is a new animal model of histotoxicity.
According to the tissue distribution of ALT activity, the
gut had the highest ALT activity among other tissues in
the silkworm. Thus, in the silkworm, increased ALT ac-
tivity appears to be induced by tissue injury in the gut.
This silkworm model would be extremely useful for
evaluating the histotoxicity of newly synthesized chemi-
cals prior to using mice or rats. We expect that the
number of mammals needed for drug development can
be reduced by first using the silkworm model.
Conclusions
The present study showed that ALT activity in the silk-
worm hemolymph is increased by the injection of vari-
ous cytotoxic drugs. The present silkworm model is
applicable for evaluating the toxicity of newly synthe-
sized compounds. This method is more sensitive than
toxicity assays based on counting the number of surviv-
ing silkworms after administration of test samples. Al-
though further validation and applied research using
other types of compounds must be performed, the use
of this silkworm model prior to the use of mammals par-
tially addresses the ethical and financial issues related to
animal experiments using mammals.
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